“Zanolimumab (HuMax-CD4®), a Fully Human Monoclonal Antibody in Clinical Development for Cutaneous T-Cell Lymphoma”. Hematology Meeting Reports, vol. 2, no. 5, June 2009, https://doi.org/10.4081/hmr.v2i5.736.